Tiger Brokers

Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million

Reuters
Yesterday
Shanghai HeartCare Medical Technology FY2025 profit before tax jumps to RMB86 million; revenue rises 46.9% to RMB408 million
  • HeartCare published an annual results announcement for the year ended Dec. 31, 2025.
  • Revenue rose 46.9% to RMB 408.3 million, and gross profit increased 59.3% to RMB 289.5 million.
  • Gross margin was 70.9%, up 5.5 percentage points, driven by a higher revenue share of higher-margin innovative products and cost reductions including production process improvements and supply chain optimization.
  • Profit before tax was RMB 86.4 million, and net profit attributable to owners of the parent was RMB 83.3 million.
  • Management said growth was supported by ischemic stroke revenue up 31.8%, hemorrhagic stroke revenue more than tripled, and interventional access revenue exceeding RMB 100.0 million, while overseas market revenue more than doubled on faster product registration and promotion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069442), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10